Small-molecule IGF1R inhibitors extend healthspan in a mouse model
Preprint
Abstract
Antagonistic pleiotropy of the IGF-1 signaling cascade is well recognized, as it promotes growth and development at younger ages and delays aging later in life. The goal of this study is to test in a mouse longevity experiment whether orally delivered small-molecule IGF1R inhibitors have promise as an anti-aging therapy. C57BL/6 mice (25 male and 25 female mice per treatment) were treated with selective IGF1R inhibitors, picropodophyllin (PPP) or 5-[3-(phenylmethoxy)phenyl]-7-[trans-3-(1-pyrrolidinylmethyl)cyclobutyl]-7H-pyrrolo[3-d]pyrimidin-4-amine (NVP-ADW742), via powdered diets starting at 13 months of age, and physiological and behavioral parameters, as well as survival, were assessed. Both compounds protected both sexes from short-term memory decline; reduced systolic blood pressure in males and pulse rate in both sexes; rescued declining glucose tolerance in males; and abolished grey hair development, reduced frailty, and protected against decline in grip strength in female mice. There were no sex differences in survival curves within groups. No significant differences between groups were observed in the Kaplan-Meier analysis. However, the survival curve in the NVP-ADW742 group was squarer than in controls, indicating a 93-day longer healthspan (p = 0.02). PPP treatment was associated with toxicity (GI bleeding). Additional analysis of the drug likeness of NVP-ADW742 demonstrated potential cardiotoxicity and brain bioaccumulation. To conclude, small-molecule IGF1R inhibitors hold promise as a therapy that may improve human health span and lifespan; however, both molecules tested in this study have side effects that may outweigh their anti-aging effects.Keywords
Funding Information
- National Institute of Aging, NIH (1R43AG085738)
This publication has 40 references indexed in Scilit:
- Statistical methods for testing effects on “maximum lifespan”Mechanisms of Ageing and Development, 2004
- The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memoryNeuroscience & Biobehavioral Reviews, 2004
- The blood–brain barrier: an overviewNeurobiology of Disease, 2004
- Regulation of Hypoxia-Inducible Factor-1α, Vascular Endothelial Growth Factor, and Angiogenesis by an Insulin-Like Growth Factor-I Receptor Autocrine Loop in Human Pancreatic CancerThe American Journal of Pathology, 2003
- IGF-1 receptor regulates lifespan and resistance to oxidative stress in miceNature, 2002
- Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genesGenome Biology, 2002
- Insulin-Like Growth Factor-1 Inscribes a Gene Expression Profile for Angiogenic Factors and Cancer Progression in Breast Epithelial CellsNeoplasia, 2002
- Insulin/IGF signalling and ageing: seeing the bigger pictureCurrent Opinion in Genetics & Development, 2001
- A Conserved Regulatory System for AgingCell, 2001
- Genetic pathways that regulate ageing in model organismsNature, 2000